Home / Resources / Dealmaking Q1 Review

Dealmaking Q1 Review

eBook
Commercial
Stock chart displaying market trends and fluctuations.

Ahead of BIO-Europe, our In Vivo journalists have explored some of the biggest deals and trends that have already shaped the start of 2024. Read on as we discuss what big pharma is looking for in strategic partners, who really were the biggest deal makers of 2023, what private equity and VC have been investing in, and why new company creation has slowed down.

Related products
Expert interview with a biopharma leader for insights and strategy.
In Vivo
Interviews, analysis and critical insights for life science decision-makers
Expert analyst presenting data insights on a projected screen.
Biomedtracker
Real-time tracking and analysis of the drug development pipeline
Collection of consumer health products that HBW Insight provides news and insights about.
HBW Insight
The single source of news and insight for the health, beauty and wellness sectors

Related resources

PDF preview of the Biomedtracker Meddevicetracker Q4 2023 Outlook Report.
FEB 01, 2024
Report
Commercial

Biomedtracker / Meddevicetracker Q4 2023 Outlook Report

Discover anticipated Q4 2023 catalysts: 32 drugs, devices, diagnostics, and deals. For each, assess Phase/PDUFA success likelihood and overall Likelihood of Approval (LOA) based on phase, drug class, and disease.

Webinar announcement featuring the panelists.
Webinar
Commercial

Deal-Making: Scouting for Expertise Webinar with Ipsen

Catch up with Ipsen and Citeline to hear the latest for deal-making, cutting through the noise to find the right deal and securing competitive alliances.